BioSpace News Archive

Revolo Biotherapeutics (“Revolo” or the “Company”) today announced that it will present the previously announced Phase 2a trial data evaluating its immune-resetting drug candidate, ‘1104, in people with eosinophilic esophagitis (EoE), via a poster at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, Canada, from October 20-25.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer’s Disease (CTAD) to be held October 24-27 in Boston, MA.

TRxADE HEALTH, INC., a parent company of pharmaceutical business-to-business exchange platform, which recently merged with Superlatus, Inc., reconfirms its commitment to pharmaceutical marketplace via its subsidiary Trxade, Inc. and is pleased to clarify its commitment to the pharmaceutical industry.

Rezolute, Inc. announced that the European Medicines Agency has granted Priority Medicines eligibility to RZ358 for the treatment of congenital hyperinsulinism.

ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.

ProPhase Labs, Inc., a next generation biotech, genomics, therapeutics and diagnostics company, unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023.

etherna, a leading mRNA/LNP technologies company, announced that Bernard Sagaert has been confirmed-as Chief Executive Officer.

Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, announced it was awarded $16.2 million by the U.S. Department of Defense to advance LMN-201 through late-stage trials.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24th at 2:30 pm ET.